Technology
Health
Pharmaceutical

Pacira BioSciences

$43.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
+$0.56 (1.29%) After Hours

Why Robinhood?

You can buy or sell PCRX and other stocks, options, ETFs, and crypto commission-free!

About

Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Read More The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Employees
518
Headquarters
Parsippany, New Jersey
Founded
2006
Market Cap
1.79B
Price-Earnings Ratio
247.80
Dividend Yield
0.00
Average Volume
596.63K
High Today
$44.03
Low Today
$43.26
Open Price
$43.62
Volume
113.14K
52 Week High
$55.00
52 Week Low
$30.00

Collections

Technology
Health
Pharmaceutical
US
North America

News

Yahoo FinanceMay 7

Pacira BioSciences to Present at Two Healthcare Conferences in May

16
Yahoo FinanceMay 7

See what the IHS Markit Score report has to say about Pacira Biosciences Inc.

Pacira Biosciences Inc NASDAQ/NGS:PCRX View full report here! Summary Bearish sentiment is low Economic output in this company's sector is expanding Bearish sentiment Short interest | Positive Short interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index ownership | Neutral E...

11
Yahoo FinanceMay 2

Pacira (PCRX) Misses Q1 Earnings Estimates

Lamb Weston (LW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Pacira (PCRX) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this specialty drugmaker would post earnings of ...

24

Earnings

-$0.03
$0.14
$0.30
$0.47
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.